NKGen Biotech, Inc. (NKGN)

NKGen Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	-	0.08	0.43
Revenue Growth (YoY)	-	-	-81.92%	-
Cost of Revenue	-	-	0.02	0.03
Gross Profit	-	-	0.06	0.4
Selling, General & Admin	16.31	14.08	7.66	7.59
Research & Development	10.66	15.67	16.75	14.67
Operating Expenses	26.97	29.75	24.41	22.26
Operating Income	-26.97	-29.75	-24.35	-21.86
Interest Expense	-2.72	-0.75	-2.31	-1.32
Other Non Operating Income (Expenses)	-30.62	-24.8	0.08	-0.08
EBT Excluding Unusual Items	-60.31	-55.29	-26.57	-23.26
Merger & Restructuring Charges	-	-3.33	-	-
Other Unusual Items	16.07	-24.33	-0.18	-
Pretax Income	-44.23	-82.95	-26.75	-23.26
Income Tax Expense	0.05	0.01	0.01	0.01
Net Income	-44.29	-82.95	-26.75	-23.27
Net Income to Common	-44.29	-82.95	-26.75	-23.27
Shares Outstanding (Basic)	29	15	6	14
Shares Outstanding (Diluted)	29	15	6	14
Shares Change (YoY)	86.88%	142.70%	-55.40%	-
EPS (Basic)	-1.54	-5.38	-4.21	-1.63
EPS (Diluted)	-1.54	-5.38	-4.21	-1.63
Free Cash Flow	-20.88	-21.95	-22.66	-19.95
Free Cash Flow Per Share	-0.72	-1.42	-3.56	-1.40
Gross Margin	-	-	76.62%	92.96%
Operating Margin	-	-	-31618.18%	-5131.69%
Profit Margin	-	-	-34745.46%	-5461.27%
Free Cash Flow Margin	-	-	-29425.97%	-4683.33%
EBITDA	-25.79	-28.54	-23.14	-20.73
D&A For EBITDA	1.18	1.2	1.21	1.13
EBIT	-26.97	-29.75	-24.35	-21.86

Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.